Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

por Hussey, Elizabeth K, Kapur, Anita, O’Connor-Semmes, Robin, Tao, Wenli, Rafferty, Bryan, Polli, Joseph W, James, Charles D, Dobbins, Robert L
Publicado 2013

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 d...

por Kapur, Anita, O’Connor-Semmes, Robin, Hussey, Elizabeth K, Dobbins, Robert L, Tao, Wenli, Hompesch, Marcus, Smith, Glenn A, Polli, Joseph W, James Jr, Charles D, Mikoshiba, Imao, Nunez, Derek J
Publicado 2013